Global Gout Therapeutics Market - 2025 -2033
Gout Therapeutics Market: Industry Outlook
The global gout therapeutics market reached US$ 2.94 billion in 2023, with a rise to US$ 3.13 billion in 2024, and is expected to reach US$ 5.55 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025–2033.
The gout therapeutics market is witnessing consistent growth, fueled by the rising global prevalence of gout and increasing awareness of lifestyle-related and metabolic disorders. Market expansion is further supported by advancements in rheumatology research, particularly in urate-lowering therapies, anti-inflammatory biologics, and novel small-molecule inhibitors. Emerging innovations such as next-generation xanthine oxidase inhibitors, biologics targeting interleukin-1 (IL-1), and personalized treatment approaches are improving disease management, reducing flare frequency, and enhancing patient outcomes.
Key Market Trends & Insights
Driver: Rising prevalence of gout worldwide
The rising prevalence of gout worldwide is expected to be a significant driver of the gout therapeutics market, as the disease is increasingly linked to modern lifestyle factors such as obesity, high-purine diets, alcohol consumption, and sedentary behavior. For instance, according to the National Kidney Foundation, In the United States, the prevalence of gout more than doubled between the 1960s and 1990s, and it is now estimated to affect 3.9% of the adult population, equivalent to approximately 8.3 million individuals, including 6.1 million men and 2.2 million women. The growing burden of comorbidities like hypertension, diabetes, and cardiovascular disorders further exacerbates hyperuricemia, leading to a higher incidence of recurrent gout flares.
With aging populations particularly vulnerable, the patient pool requiring both acute and long-term management continues to expand rapidly. This surge in cases is driving strong demand for effective treatment options, ranging from widely used NSAIDs to advanced urate-lowering therapies and biologics, thereby propelling growth in the global market.
Restraint: Side effects and safety concerns
Side effects and safety concerns pose a significant challenge to the growth of the gout therapeutics market, as they directly impact patient compliance and physician prescribing patterns. Long-term use of commonly prescribed treatments such as NSAIDs, corticosteroids, and urate-lowering therapies is often associated with adverse effects, including gastrointestinal complications, cardiovascular risks, kidney impairment, and liver toxicity.
Gout Therapeutics Market Segment Analysis
The global gout therapeutics market is segmented by disease type, drug class, distribution channel, and region.
Drug Class:
The non-steroidal anti-inflammatory drugs (NSAIDs) segment is estimated to have 39.4% of the gout therapeutics market share.
Non-steroidal anti-inflammatory drugs (NSAIDs) are expected to remain the dominant segment in the gout therapeutics market, primarily due to their widespread use as the first-line treatment for managing acute gout flares. Their rapid ability to relieve pain and inflammation, combined with broad availability, low cost, and established physician familiarity, makes them the most prescribed option across both developed and emerging markets.
Despite the growing adoption of biologics and advanced urate-lowering therapies for long-term disease management, NSAIDs continue to be favored for immediate symptom control, ensuring their strong market presence. The segment’s dominance is further supported by the availability of multiple generic options, strong patient accessibility through retail and hospital pharmacies, and ongoing demand in regions with limited access to advanced biologics.
Gout Therapeutics Market - Geographical Analysis
The North America gout therapeutics market was valued at 39.7% market share in 2024
North America dominates the gout therapeutics market, accounting for the largest revenue share, and is expected to maintain its leadership throughout the forecast period. This dominance is underpinned by a high prevalence of gout linked to hypertension and metabolic syndrome, coupled with strong awareness and high diagnosis rates across the region. Substantial R&D investments and the presence of leading pharmaceutical companies have accelerated the development and commercialization of innovative urate-lowering therapies, biologics, and anti-inflammatory drugs.
Additionally, favorable regulatory frameworks, including expedited approval pathways and Orphan Drug designations, support faster market entry for novel treatments. For instance, in August 2024, Scilex Holding Company announced that the U.S. Food and Drug Administration (FDA) had approved a Supplemental New Drug Application (sNDA) for label updates to GLOPERBA. Widespread access to health insurance, early adoption of advanced therapeutics, and strong physician and patient awareness further reinforce North America’s position as the most established and lucrative market for gout therapeutics.
The Asia-Pacific gout therapeutics market was valued at 18.30% market share in 2024
Asia-Pacific is expected to be the fastest-growing region in the gout therapeutics market, driven by the rising prevalence of gout due to lifestyle changes, aging populations, and increasing dietary risk factors in countries such as China, India, and Japan.
Greater access to diagnostic tools and growing government initiatives to improve chronic disease management are further accelerating treatment adoption. The rapid expansion of retail and online pharmacy networks is enhancing drug accessibility, while pharmaceutical companies are investing in clinical trials and local partnerships to introduce innovative urate-lowering therapies and biologics. For instance, in December 2024, the National Medical Products Administration (NMPA) in China approved URECE for the treatment of gout patients with hyperuricemia. Developed by FUJI YAKUHIN, URECE represents a novel therapeutic option designed to address the growing need for effective management of gout and hyperuricemia.
Gout Therapeutics Market Major Players
The major players in the gout therapeutics market include Takeda Pharmaceutical Company Limited, Novartis Pharmaceuticals Corporation, Amgen Inc., Lupin, AstraZeneca, among others.
The global gout therapeutics market report delivers a detailed analysis with 73 key tables, more than 76 visually impactful figures, and 195 pages of expert insights, providing a complete view of the market landscape.
The global gout therapeutics market reached US$ 2.94 billion in 2023, with a rise to US$ 3.13 billion in 2024, and is expected to reach US$ 5.55 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025–2033.
The gout therapeutics market is witnessing consistent growth, fueled by the rising global prevalence of gout and increasing awareness of lifestyle-related and metabolic disorders. Market expansion is further supported by advancements in rheumatology research, particularly in urate-lowering therapies, anti-inflammatory biologics, and novel small-molecule inhibitors. Emerging innovations such as next-generation xanthine oxidase inhibitors, biologics targeting interleukin-1 (IL-1), and personalized treatment approaches are improving disease management, reducing flare frequency, and enhancing patient outcomes.
Key Market Trends & Insights
- North America accounted for approximately 39.7% of the global Gout Therapeutics market in 2024 and is expected to retain its leading position throughout the forecast period. This dominance is driven by high diagnosis and treatment rates, substantial R&D investments in urate-lowering therapies and biologics, and strong regulatory support enabling faster approvals of novel therapeutics.
- Asia-Pacific is projected to be the fastest-growing region, propelled by the rising prevalence of gout linked to changing dietary habits and sedentary lifestyles, expanding healthcare access, growing patient awareness, and increasing government initiatives to improve management of chronic diseases.
- NSAIDs remain the dominant treatment segment, owing to their widespread use as first-line therapy for acute gout flares.
- 2024 Market Size: US$ 2.94 Billion
- 2033 Projected Market Size: US$ 5.55 Billion
- CAGR (2025–2033): 7.4%
- North America: Largest market in 2024
- Asia Pacific: Fastest-growing market
Driver: Rising prevalence of gout worldwide
The rising prevalence of gout worldwide is expected to be a significant driver of the gout therapeutics market, as the disease is increasingly linked to modern lifestyle factors such as obesity, high-purine diets, alcohol consumption, and sedentary behavior. For instance, according to the National Kidney Foundation, In the United States, the prevalence of gout more than doubled between the 1960s and 1990s, and it is now estimated to affect 3.9% of the adult population, equivalent to approximately 8.3 million individuals, including 6.1 million men and 2.2 million women. The growing burden of comorbidities like hypertension, diabetes, and cardiovascular disorders further exacerbates hyperuricemia, leading to a higher incidence of recurrent gout flares.
With aging populations particularly vulnerable, the patient pool requiring both acute and long-term management continues to expand rapidly. This surge in cases is driving strong demand for effective treatment options, ranging from widely used NSAIDs to advanced urate-lowering therapies and biologics, thereby propelling growth in the global market.
Restraint: Side effects and safety concerns
Side effects and safety concerns pose a significant challenge to the growth of the gout therapeutics market, as they directly impact patient compliance and physician prescribing patterns. Long-term use of commonly prescribed treatments such as NSAIDs, corticosteroids, and urate-lowering therapies is often associated with adverse effects, including gastrointestinal complications, cardiovascular risks, kidney impairment, and liver toxicity.
Gout Therapeutics Market Segment Analysis
The global gout therapeutics market is segmented by disease type, drug class, distribution channel, and region.
Drug Class:
The non-steroidal anti-inflammatory drugs (NSAIDs) segment is estimated to have 39.4% of the gout therapeutics market share.
Non-steroidal anti-inflammatory drugs (NSAIDs) are expected to remain the dominant segment in the gout therapeutics market, primarily due to their widespread use as the first-line treatment for managing acute gout flares. Their rapid ability to relieve pain and inflammation, combined with broad availability, low cost, and established physician familiarity, makes them the most prescribed option across both developed and emerging markets.
Despite the growing adoption of biologics and advanced urate-lowering therapies for long-term disease management, NSAIDs continue to be favored for immediate symptom control, ensuring their strong market presence. The segment’s dominance is further supported by the availability of multiple generic options, strong patient accessibility through retail and hospital pharmacies, and ongoing demand in regions with limited access to advanced biologics.
Gout Therapeutics Market - Geographical Analysis
The North America gout therapeutics market was valued at 39.7% market share in 2024
North America dominates the gout therapeutics market, accounting for the largest revenue share, and is expected to maintain its leadership throughout the forecast period. This dominance is underpinned by a high prevalence of gout linked to hypertension and metabolic syndrome, coupled with strong awareness and high diagnosis rates across the region. Substantial R&D investments and the presence of leading pharmaceutical companies have accelerated the development and commercialization of innovative urate-lowering therapies, biologics, and anti-inflammatory drugs.
Additionally, favorable regulatory frameworks, including expedited approval pathways and Orphan Drug designations, support faster market entry for novel treatments. For instance, in August 2024, Scilex Holding Company announced that the U.S. Food and Drug Administration (FDA) had approved a Supplemental New Drug Application (sNDA) for label updates to GLOPERBA. Widespread access to health insurance, early adoption of advanced therapeutics, and strong physician and patient awareness further reinforce North America’s position as the most established and lucrative market for gout therapeutics.
The Asia-Pacific gout therapeutics market was valued at 18.30% market share in 2024
Asia-Pacific is expected to be the fastest-growing region in the gout therapeutics market, driven by the rising prevalence of gout due to lifestyle changes, aging populations, and increasing dietary risk factors in countries such as China, India, and Japan.
Greater access to diagnostic tools and growing government initiatives to improve chronic disease management are further accelerating treatment adoption. The rapid expansion of retail and online pharmacy networks is enhancing drug accessibility, while pharmaceutical companies are investing in clinical trials and local partnerships to introduce innovative urate-lowering therapies and biologics. For instance, in December 2024, the National Medical Products Administration (NMPA) in China approved URECE for the treatment of gout patients with hyperuricemia. Developed by FUJI YAKUHIN, URECE represents a novel therapeutic option designed to address the growing need for effective management of gout and hyperuricemia.
Gout Therapeutics Market Major Players
The major players in the gout therapeutics market include Takeda Pharmaceutical Company Limited, Novartis Pharmaceuticals Corporation, Amgen Inc., Lupin, AstraZeneca, among others.
The global gout therapeutics market report delivers a detailed analysis with 73 key tables, more than 76 visually impactful figures, and 195 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY DISEASE TYPE
4.1. Snippet by Drug Class
5. SNIPPET BY DISTRIBUTION CHANNEL
5.1. Snippet by Region
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Prevalence of Gout Worldwide
6.1.1.2. Advancements in Therapeutics
6.1.2. Restraints
6.1.2.1. Side Effects and Safety Concerns
6.1.2.2. High Cost of Advanced Biologics and Targeted Therapies
6.1.3. Opportunity
6.1.3.1. Rising Demand in Asia-Pacific and Emerging Markets
6.1.3.2. Strategic Collaborations and Partnerships
6.1.4. Impact Analysis
7. GLOBAL GOUT THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
7.1. Market Leaders and Pioneers
7.1.1. Emerging Pioneers and Prominent Players
7.1.2. Established leaders with largest largest-selling Brand
7.1.3. Market leaders with established products & Services
7.2. Latest Developments and Breakthroughs
7.3. Regulatory and Reimbursement Landscape
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. South America
7.3.5. Middle East & Africa
7.4. Porter’s Five Force Analysis
7.5. Supply Chain Analysis
7.6. Patent Analysis
7.7. SWOT Analysis
7.8. Unmet Needs and Gaps
7.9. Recommended Strategies for Market Entry and Expansion
7.10. Pricing Analysis and Price Dynamics
8. GLOBAL GOUT THERAPEUTICS MARKET: BY DISEASE TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type
8.2. Primary Gout*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Secondary Gout
9. GLOBAL GOUT THERAPEUTICS MARKET: BY DRUG CLASS
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Colchicine
9.4. Corticosteroids
9.5. Uricosuric Medications
9.6. Others
10. GLOBAL GOUT THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Drug Stores
10.4. E-commerce
10.5. Others
11. REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
12. INTRODUCTION
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.1. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. U.K.
12.3.6.3. France
12.3.6.4. Spain
12.3.6.5. Italy
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. South Korea
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
14. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
14.1. Market Share Analysis and Positioning Matrix
14.2. Strategic Partnerships, Mergers & Acquisitions
14.3. Key Developments in Product Portfolios and Innovations
14.4. Company Benchmarking
15. COMPANY PROFILES
15.1. Takeda Pharmaceutical Company Limited*
15.1.1. Company Overview
15.1.2. Product Portfolio
15.1.2.1. Product Description
15.1.2.2. Product Key Performance Indicators (KPIs)
15.1.2.3. Historic and Forecasted Product Sales
15.1.2.4. Product Sales Volume
16. FINANCIAL OVERVIEW
16.1. Company Revenue
16.1.1. Geographical Revenue Shares
16.1.1.1. Revenue Forecasts
16.1.2. Key Developments
16.1.2.1. Mergers & Acquisitions
16.1.2.2. Key Product Development Activities
16.1.2.3. Regulatory Approvals, etc.
16.1.3. SWOT Analysis
16.2. Novartis Pharmaceuticals Corporation
16.3. Amgen Inc.
16.4. Lupin
16.5. AstraZeneca
LIST NOT EXHAUSTIVE
1. ASSUMPTIONS AND RESEARCH METHODOLOGY
1. DATA COLLECTION METHODS
2. DATA TRIANGULATION
3. FORECASTING TECHNIQUES
4. DATA VERIFICATION AND VALIDATION
2. APPENDIX
1. ABOUT US AND SERVICES
2. CONTACT US
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY DISEASE TYPE
4.1. Snippet by Drug Class
5. SNIPPET BY DISTRIBUTION CHANNEL
5.1. Snippet by Region
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Prevalence of Gout Worldwide
6.1.1.2. Advancements in Therapeutics
6.1.2. Restraints
6.1.2.1. Side Effects and Safety Concerns
6.1.2.2. High Cost of Advanced Biologics and Targeted Therapies
6.1.3. Opportunity
6.1.3.1. Rising Demand in Asia-Pacific and Emerging Markets
6.1.3.2. Strategic Collaborations and Partnerships
6.1.4. Impact Analysis
7. GLOBAL GOUT THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
7.1. Market Leaders and Pioneers
7.1.1. Emerging Pioneers and Prominent Players
7.1.2. Established leaders with largest largest-selling Brand
7.1.3. Market leaders with established products & Services
7.2. Latest Developments and Breakthroughs
7.3. Regulatory and Reimbursement Landscape
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. South America
7.3.5. Middle East & Africa
7.4. Porter’s Five Force Analysis
7.5. Supply Chain Analysis
7.6. Patent Analysis
7.7. SWOT Analysis
7.8. Unmet Needs and Gaps
7.9. Recommended Strategies for Market Entry and Expansion
7.10. Pricing Analysis and Price Dynamics
8. GLOBAL GOUT THERAPEUTICS MARKET: BY DISEASE TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type
8.2. Primary Gout*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Secondary Gout
9. GLOBAL GOUT THERAPEUTICS MARKET: BY DRUG CLASS
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Colchicine
9.4. Corticosteroids
9.5. Uricosuric Medications
9.6. Others
10. GLOBAL GOUT THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Drug Stores
10.4. E-commerce
10.5. Others
11. REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
12. INTRODUCTION
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.1. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. U.K.
12.3.6.3. France
12.3.6.4. Spain
12.3.6.5. Italy
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. South Korea
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
14. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
14.1. Market Share Analysis and Positioning Matrix
14.2. Strategic Partnerships, Mergers & Acquisitions
14.3. Key Developments in Product Portfolios and Innovations
14.4. Company Benchmarking
15. COMPANY PROFILES
15.1. Takeda Pharmaceutical Company Limited*
15.1.1. Company Overview
15.1.2. Product Portfolio
15.1.2.1. Product Description
15.1.2.2. Product Key Performance Indicators (KPIs)
15.1.2.3. Historic and Forecasted Product Sales
15.1.2.4. Product Sales Volume
16. FINANCIAL OVERVIEW
16.1. Company Revenue
16.1.1. Geographical Revenue Shares
16.1.1.1. Revenue Forecasts
16.1.2. Key Developments
16.1.2.1. Mergers & Acquisitions
16.1.2.2. Key Product Development Activities
16.1.2.3. Regulatory Approvals, etc.
16.1.3. SWOT Analysis
16.2. Novartis Pharmaceuticals Corporation
16.3. Amgen Inc.
16.4. Lupin
16.5. AstraZeneca
LIST NOT EXHAUSTIVE
1. ASSUMPTIONS AND RESEARCH METHODOLOGY
1. DATA COLLECTION METHODS
2. DATA TRIANGULATION
3. FORECASTING TECHNIQUES
4. DATA VERIFICATION AND VALIDATION
2. APPENDIX
1. ABOUT US AND SERVICES
2. CONTACT US
LIST OF TABLES
Table 1 Global Gout Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Gout Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Gout Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Gout Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Gout Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 7 Global Gout Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 9 Global Gout Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Gout Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Gout Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 14 North America Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 15 North America Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 22 Europe Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 23 Europe Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Europe Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 26 South America Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 27 South America Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Takeda Pharmaceutical Company Limited: Overview
Table 34 Takeda Pharmaceutical Company Limited: Product Portfolio
Table 35 Takeda Pharmaceutical Company Limited: Key Developments
Table 36 Novartis Pharmaceuticals Corporation: Overview
Table 37 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 38 Novartis Pharmaceuticals Corporation: Key Developments
Table 39 Amgen Inc.: Overview
Table 40 Amgen Inc.: Product Portfolio
Table 41 Amgen Inc.: Key Developments
Table 42 Lupin: Overview
Table 43 Lupin: Product Portfolio
Table 44 Lupin: Key Developments
Table 45 AstraZeneca: Overview
Table 46 AstraZeneca: Product Portfolio
Table 47 AstraZeneca: Key Developments
Table 1 Global Gout Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Gout Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Gout Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Gout Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Gout Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 7 Global Gout Therapeutics Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 9 Global Gout Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Gout Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Gout Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 14 North America Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 15 North America Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 22 Europe Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 23 Europe Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Europe Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 26 South America Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 27 South America Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Gout Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Gout Therapeutics Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Gout Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Gout Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Takeda Pharmaceutical Company Limited: Overview
Table 34 Takeda Pharmaceutical Company Limited: Product Portfolio
Table 35 Takeda Pharmaceutical Company Limited: Key Developments
Table 36 Novartis Pharmaceuticals Corporation: Overview
Table 37 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 38 Novartis Pharmaceuticals Corporation: Key Developments
Table 39 Amgen Inc.: Overview
Table 40 Amgen Inc.: Product Portfolio
Table 41 Amgen Inc.: Key Developments
Table 42 Lupin: Overview
Table 43 Lupin: Product Portfolio
Table 44 Lupin: Key Developments
Table 45 AstraZeneca: Overview
Table 46 AstraZeneca: Product Portfolio
Table 47 AstraZeneca: Key Developments
LIST OF FIGURES
Figure 1 Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 3 Global Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 4 Global Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Gout Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Gout Therapeutics Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 7 Primary Gout Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 8 Secondary Gout Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Global Gout Therapeutics Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)
Figure 10 Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 11 Colchicine Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 12 Corticosteroids Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 13 Uricosuric Medications Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 14 Others Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Global Gout Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 16 Hospital Pharmacies Distribution Channel in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Drug Stores Distribution Channel in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 E-commerce Distribution Channel in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Distribution Channel in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Gout Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 23 North America Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 24 North America Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 25 North America Gout Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 26 Asia-Pacific Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 27 Asia-Pacific Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 28 Asia-Pacific Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 29 Asia-Pacific Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 30 Asia-Pacific Gout Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 33 Europe Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 34 Europe Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 Europe Gout Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 36 South America Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 37 South America Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 38 South America Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 39 South America Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 South America Gout Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 41 Middle East and Africa Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 42 Middle East and Africa Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 43 Middle East and Africa Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 44 Middle East and Africa Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 Takeda Pharmaceutical Company Limited: Financials
Figure 46 Novartis Pharmaceuticals Corporation: Financials
Figure 47 Amgen Inc.: Financials
Figure 48 Lupin: Financials
Figure 49 AstraZeneca: Financials
Figure 1 Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 3 Global Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 4 Global Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Gout Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Gout Therapeutics Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 7 Primary Gout Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 8 Secondary Gout Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Global Gout Therapeutics Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)
Figure 10 Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 11 Colchicine Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 12 Corticosteroids Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 13 Uricosuric Medications Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 14 Others Drug Class in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Global Gout Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 16 Hospital Pharmacies Distribution Channel in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Drug Stores Distribution Channel in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 E-commerce Distribution Channel in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Distribution Channel in Global Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Gout Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 23 North America Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 24 North America Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 25 North America Gout Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 26 Asia-Pacific Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 27 Asia-Pacific Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 28 Asia-Pacific Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 29 Asia-Pacific Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 30 Asia-Pacific Gout Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 33 Europe Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 34 Europe Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 Europe Gout Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 36 South America Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 37 South America Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 38 South America Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 39 South America Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 South America Gout Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 41 Middle East and Africa Gout Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 42 Middle East and Africa Gout Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 43 Middle East and Africa Gout Therapeutics Market Share, By Drug Class, 2024 & 2033 (%)
Figure 44 Middle East and Africa Gout Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 Takeda Pharmaceutical Company Limited: Financials
Figure 46 Novartis Pharmaceuticals Corporation: Financials
Figure 47 Amgen Inc.: Financials
Figure 48 Lupin: Financials
Figure 49 AstraZeneca: Financials
